Delving into the Latest Updates on Octapharma AB with Synapse

Overview

Tags

Congenital Disorders

Hemic and Lymphatic Diseases

Other Diseases

Recombinant coagulation factor

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Recombinant coagulation factor	1

Top 5 Target	Count

F8(Coagulation factor VIII)	1

To evaluate the clinical efficacy of Human-cl rhFVIII in the prevention and treatment of bleeding events (BE). To define pharmacokinetic characteristics, determine incremental in vivo recovery - at study entry and over time, investigate potential immunogenicity, evaluate the efficacy of Human-cl rhFVIII as a surgical prophylaxis, and assess safety.

Start Date29 Jun 2018

Sponsor / Collaborator

Parexel China Co.,Ltd.

[+2]

100 Clinical Results associated with Octapharma AB

Login to view more data

0 Patents (Medical) associated with Octapharma AB

Login to view more data

100 Deals associated with Octapharma AB

Login to view more data

100 Translational Medicine associated with Octapharma AB

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data